ATE226075T1 - Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid - Google Patents

Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid

Info

Publication number
ATE226075T1
ATE226075T1 AT96921929T AT96921929T ATE226075T1 AT E226075 T1 ATE226075 T1 AT E226075T1 AT 96921929 T AT96921929 T AT 96921929T AT 96921929 T AT96921929 T AT 96921929T AT E226075 T1 ATE226075 T1 AT E226075T1
Authority
AT
Austria
Prior art keywords
monoglyceride
pharmaceutical composition
composition containing
proteinase inhibitor
compositions
Prior art date
Application number
AT96921929T
Other languages
English (en)
Inventor
Carole Anne Bailey
Josephine Christine Ferdinando
Navnit Shah
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/616,233 external-priority patent/US6008228A/en
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE226075T1 publication Critical patent/ATE226075T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT96921929T 1995-06-06 1996-06-04 Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid ATE226075T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46849395A 1995-06-06 1995-06-06
US08/616,233 US6008228A (en) 1995-06-06 1996-05-07 Pharmaceutical compositions containing proteinase inhibitors
PCT/EP1996/002431 WO1996039142A1 (en) 1995-06-06 1996-06-04 Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride

Publications (1)

Publication Number Publication Date
ATE226075T1 true ATE226075T1 (de) 2002-11-15

Family

ID=27042422

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96921929T ATE226075T1 (de) 1995-06-06 1996-06-04 Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid

Country Status (27)

Country Link
EP (1) EP0831826B1 (de)
JP (1) JP3238412B2 (de)
CN (1) CN1092960C (de)
AT (1) ATE226075T1 (de)
AU (1) AU709796B2 (de)
BG (1) BG63711B1 (de)
BR (1) BR9610842A (de)
CA (1) CA2224125C (de)
CY (1) CY2373B1 (de)
CZ (1) CZ292192B6 (de)
DE (1) DE69624354T2 (de)
DK (1) DK0831826T3 (de)
EA (1) EA001413B1 (de)
ES (1) ES2182996T3 (de)
HK (1) HK1010136A1 (de)
HU (1) HU223899B1 (de)
IL (1) IL122353A0 (de)
IS (1) IS2661B (de)
MX (1) MX9709193A (de)
NO (1) NO324531B1 (de)
NZ (1) NZ311646A (de)
OA (1) OA10546A (de)
PL (1) PL184820B1 (de)
PT (1) PT831826E (de)
SK (1) SK282121B6 (de)
TR (1) TR199701541T1 (de)
WO (1) WO1996039142A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69804624T2 (de) 1997-07-29 2002-09-19 Upjohn Co Selbstemulgierende formulierung enthaltend lipophile verbindungen
SI0989851T1 (en) 1997-07-29 2003-04-30 Pharmacia & Upjohn Company Self-emulsifying formulation for acidic lipophilic compounds
CN1232244C (zh) * 1999-02-08 2005-12-21 阿尔萨公司 稳定的非水性单相粘性载体及采用该载体的制剂
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US6956048B2 (en) 1999-03-31 2005-10-18 Pharmacia & Upjohn Company Pharmaceutical emulsions for retroviral protease inhibitors
US6309663B1 (en) * 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BR0202252A (pt) 2002-06-12 2004-06-29 Cristalia Prod Quimicos Farm Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
DE602007009377D1 (de) 2006-05-30 2010-11-04 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2008244523B2 (en) 2007-04-23 2012-02-16 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
EP2240155B1 (de) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Vorrichtungen, formulierungen und verfahren zur freisetzung mehrerer wirkstoffe
EP2108705A1 (de) 2008-04-08 2009-10-14 Universität Duisburg-Essen Verfahren zur Analyse der epigenetischen Lage des HtrA1 Gens in einer biologischen Probe
SI2462246T1 (en) 2009-09-28 2018-01-31 Intarcia Therapeutics, Inc. Fast-setting and / or cessation of substantially unchanged delivery of the product
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR20240042548A (ko) 2015-06-03 2024-04-02 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
EP3565580B1 (de) 2017-01-03 2024-03-06 i2o Therapeutics, Inc. Kontinuierlicher verabreichung von exenatid und co-verabreichung von acetaminophen, ethinylestradiol oder levonorgestrel

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor

Also Published As

Publication number Publication date
AU709796B2 (en) 1999-09-09
CZ292192B6 (cs) 2003-08-13
OA10546A (en) 2002-05-29
BG102106A (en) 1998-08-31
TR199701541T1 (xx) 1998-03-21
EP0831826A1 (de) 1998-04-01
SK162797A3 (en) 1998-05-06
JPH10507202A (ja) 1998-07-14
AU6300496A (en) 1996-12-24
CA2224125C (en) 2004-09-28
CY2373B1 (en) 2004-06-04
CN1092960C (zh) 2002-10-23
IS2661B (is) 2010-08-15
ES2182996T3 (es) 2003-03-16
JP3238412B2 (ja) 2001-12-17
NZ311646A (en) 2000-02-28
CA2224125A1 (en) 1996-12-12
PL184820B1 (pl) 2002-12-31
NO975665L (no) 1998-02-05
IL122353A0 (en) 1998-04-05
MX9709193A (es) 1998-03-31
NO324531B1 (no) 2007-11-12
DE69624354T2 (de) 2003-06-05
BR9610842A (pt) 1999-07-13
WO1996039142A1 (en) 1996-12-12
EA001413B1 (ru) 2001-02-26
IS4627A (is) 1997-12-04
PT831826E (pt) 2003-02-28
HK1010136A1 (en) 1999-06-17
DE69624354D1 (de) 2002-11-21
HUP9801905A2 (hu) 1999-05-28
HU223899B1 (hu) 2005-03-29
SK282121B6 (sk) 2001-11-06
PL323860A1 (en) 1998-04-27
DK0831826T3 (da) 2003-02-03
EP0831826B1 (de) 2002-10-16
CZ380397A3 (cs) 1998-03-18
EA199800023A1 (ru) 1998-08-27
HUP9801905A3 (en) 2001-04-28
BG63711B1 (bg) 2002-10-31
NO975665D0 (no) 1997-12-05
CN1186434A (zh) 1998-07-01

Similar Documents

Publication Publication Date Title
ATE226075T1 (de) Pharmazeutische zusammensetzung enthaltend einen inhibitor von proteinase und einen monoglycerid
DK1915993T3 (da) Synergistiske kombinationer omfattende en renininhibitor til hjertekarsygdomme
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
HUP9901410A3 (en) Nitrile derivatives as inhibitors of tumor necrosis factor alpha and pharmaceutical compositions containing them
ATE214610T1 (de) Neuartige pharmazeutische verwendungen von krill- enzymen
MY116525A (en) Pharmaceutical composition comprising a proteinase inhibitor and a monoglyceride
IL122942A0 (en) Esters of 1-beta-d-arabinofuranosylcytosine and pharmaceutical compositions containing them
NZ502133A (en) Method of enhancing bioavailability of fexofenadine and its derivatives
TR199800954T2 (xx) Y�ksek i�erikli famsiklovir tabletleri.
IL138574A0 (en) Amidino protease inhibitors and pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0831826

Country of ref document: EP